Aldeyra Therapeutics, Inc. (ALDX)
1.22
-0.13
(-9.63%)
USD |
NASDAQ |
Sep 24, 16:00
1.29
+0.07
(+5.74%)
Pre-Market: 08:30
Aldeyra Therapeutics Enterprise Value : 28.65M for Sept. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 24, 2026 | 28.65M |
| September 23, 2026 | 36.49M |
| September 22, 2026 | 39.20M |
| September 21, 2026 | 36.49M |
| September 18, 2026 | 37.09M |
| September 17, 2026 | 38.30M |
| September 16, 2026 | 37.69M |
| September 15, 2026 | 37.69M |
| September 14, 2026 | 43.12M |
| September 11, 2026 | 35.88M |
| September 10, 2026 | 43.12M |
| September 09, 2026 | 45.54M |
| September 08, 2026 | 47.95M |
| September 04, 2026 | 44.33M |
| September 03, 2026 | 44.33M |
| September 02, 2026 | 44.93M |
| September 01, 2026 | 44.93M |
| August 31, 2026 | 44.33M |
| August 28, 2026 | 44.63M |
| August 27, 2026 | 47.95M |
| August 26, 2026 | 49.15M |
| August 25, 2026 | 48.55M |
| August 24, 2026 | 46.74M |
| August 21, 2026 | 46.74M |
| August 20, 2026 | 45.54M |
| Date | Value |
|---|---|
| August 19, 2026 | 50.36M |
| August 18, 2026 | 48.55M |
| August 17, 2026 | 49.15M |
| August 14, 2026 | 49.15M |
| August 13, 2026 | 41.92M |
| August 12, 2026 | 46.74M |
| August 11, 2026 | 46.14M |
| August 10, 2026 | 46.14M |
| August 07, 2026 | 48.55M |
| August 06, 2026 | 50.96M |
| August 05, 2026 | 51.57M |
| August 04, 2026 | 48.55M |
| August 03, 2026 | 47.34M |
| July 31, 2026 | 47.95M |
| July 30, 2026 | 51.57M |
| July 29, 2026 | 52.17M |
| July 28, 2026 | 50.36M |
| July 27, 2026 | 50.66M |
| July 24, 2026 | 46.74M |
| July 23, 2026 | 48.55M |
| July 22, 2026 | 57.60M |
| July 21, 2026 | 60.62M |
| July 20, 2026 | 57.60M |
| July 17, 2026 | 57.00M |
| July 16, 2026 | 58.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.100B |
| Oncolytics Biotech, Inc. | 80.99M |
| Sangamo Therapeutics, Inc. | 52.69M |
| Sarepta Therapeutics, Inc. | 2.200B |
| Anixa Biosciences, Inc. | 81.18M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.450M |
| Total Expenses (Quarterly) | 5.450M |
| EPS Diluted (Quarterly) | -0.0904 |
| Earnings Yield | -31.39% |
| Normalized Earnings Yield | -31.39 |